To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
The technical storage or access that is used exclusively for statistical purposes.
The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
In this interview with The Medicine Maker, our CEO Alexander Seyf discusses why the UK has lost momentum in CGT, the real bottlenecks standing between clinical success and commercial delivery, and why digitalisation is no longer optional for scalable manufacturing.
“Digital is not a ‘good to have,’ it’s a necessity,” says Seyf. “We cannot possibly produce more without having a digital platform.”
He also shares why information sharing and cross-sector collaboration will determine which regions lead the next phase of CGT growth.
Read the full interview – including why Alexander believes China could become the dominant player in CGT within 3–5 years – here.